Logo
TMO logo
Thermo Fisher Scientific Inc.
TMO
524.71 (2.86%) 15.00
Health Care
Life Sciences Tools and Services
Thermo Fisher Scientific Inc. provides life sciences solutions analytical instruments specialty diagnostics and laboratory products and biopharma services in the North America Europe Asia-Pacific and internationally. It operates through four segments: Life Sciences Solutions Analytical Instruments Specialty Diagnostics and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents instruments and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments consumables software and services for pharmaceutical biotechnology academic government environmental and other research and industrial markets as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits calibrators controls protein detection assays and instruments; immunodiagnostic offerings comprising developing manufacturing and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy asthma and autoimmune diseases; microbiology offerings such as dehydrated and prepared culture media collection and transport systems instrumentation and consumables to detect pathogens in blood diagnostic and rapid direct specimen tests quality-control products and associated products; transplant diagnostics products including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products research and safety market channel and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham Massachusetts.

Quality Checklist 5/8

5Y Shares Out Change < 0%
Debt/Equity < 1
Current Ratio > 1
Net Margin > 10%
Est. EPS Growth > 5%
ROIC > 10%
Quick Ratio > 1
Past Net Income CAGR > 0%
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $194.99(B)
EV: $259.09(B)
Total Equity: $52.06(B)
Earnings date: Jul-22-2026
P/E: 28.77
Forward P/E: 21.12
P/FCF: 28.89
P/S: 4.36
P/B: 3.75
EPS: $18.2
EPS (fwd): $24.9
FCF/share: $18.2
Revenue/share: $120.4
Book value/share: $139.8
ROIC: 7.7%
ROA: 6.5%
ROE: 13.1%
Debt/Equity: 0.83
Current Ratio: 1.50
Gross margin: 40.9%
Operating margin: 18.4%
Net margin: 15.2%
Dividend/share: $1.8
Div. yield: 0.34%
All Valuation Overview Growth Financials & KPIsCompetitors & Peer Comparison Ownership Tools

TMO Valuation & Price Targets

Current Price
$525

Favorite Valuation Methods

PEvaluation
N/A
Analyst targets
N/A
DCF (2-stage)
N/A

More Valuation Methods

DCF (simple)
N/A
N/A
DCF (exit mult.)
N/A
N/A
DDM
N/A
N/A
EPS growth
N/A
N/A
Revenue growth
N/A
N/A
Peter Lynch FV
N/A
N/A
Graham No.
N/A
N/A

PEvaluation

24% overvalued
Low
$301
Mid
$401
High
$501
Current price
$525
Fair P/E
Margin of safety
EPS
Market Model
ROICRevenue growthFCF MarginShares outstan...Debt/EquityDebt/EBITDA
Economic moat: Medium

EPS Estimates

LowAvgHigh#
FY+124.624.925.026
FY+226.327.329.126
FY+328.630.231.717
FY+432.534.236.45
FY+535.638.041.53

Analyst Price Targets

14% undervalued
Low
$490
Mid
$600
High
$750
Current price
$525

Analyst Recommendations

Strong Buy5
Buy18
Hold6
Sell0
Strong Sell0

2-stage DCF

First Stage Duration: 5 Years
Starting Free Cash Flow
First Stage Growth Rate
LowMidHigh
Terminal Growth Rate
LowMidHigh
Discount Rate

Discounted Cash Flow

Forecast years: 5 Years
Terminal Growth Rate
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Discounted Cash Flow (exit mult.)

Forecast years: 5 Years
Exit FCF Multiple
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Dividend Discount Model

Annual Dividend
First Stage Length (Years): 0 Years
First Stage Growth Rate
Final Growth Rate
Discount Rate

EPS Growth

Forecast years: 5 Years
Starting EPS
EPS Growth Rate
LowMidHigh
Final P/E
LowMidHigh
Discount Rate

Revenue Growth Valuation

Forecast Years: 10 Years
Base Revenue
Revenue Growth Rate
LowMidHigh
Final Net Margin
LowMidHigh
Final P/E Ratio
LowMidHigh
Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate

Graham Formula

Earnings Per Share
EPS Growth (7-10 years)
Government Bond Rate
(C) PEVALUATOR
About
Terms & privacy
Price charts & news courtesy of TradingView
Blog
Contact